Bilder RM (1997). Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 42:255-264. Cancro R, Lehmann HE (2000). Schizophrenia: Clinical features. In Sadock BJ, Sadock VA (eds). Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 7th ed. Lippincott, Williams, and Wilkins: Philadelphia, pp. 1169-1199. Carson WH, Ali M, Saha GC, Dunbar GC, Ingenito G (2001). A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Presented at the annual meeting of the American Psychiatric Association, May 7-12, 2001, New Orleans. Casey DE (1995). Motor and mental aspects of EPS. Int Clin Psychopharmacol, 10:105-114. Casey DE, Daniel D, Tracy K, Wozniak P, Sommerville K (2001). Improved antipsychotic effect of divalproex combined with risperidone or olanzapine for schizophrenia. Presented at the World Assembly of Mental Health, Vancouver, July 22-27, 2001. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. Am J Psychiatry 158:518-526.

Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-485. Delay J, Deniker P (1952). Le traitement des psychoses par une methode neurolyque derivee de l'hibernotherapie. Congres des Medicins Alienistes et Neurologistes de France. Masson Editeurs Libraires de France: Paris, pp. 497-502. DeQuardo JR, Tandon R (1998). Do atypical antipsychotic medications favorably alter the long-

term course of schizophrenia? J Psychiatr Res 32:229-242. Fink M, Sackeim HA (1996). Convulsive therapy in schizophrenia? Schizophr Bull 22:27-42.

Geddes JR, Harrison PJ (1997). Closing the gap between research and practice. Br J Psychiatry 171:220-225.

Gilbert PL, Harris MJ, McAdams LA, et al. (1995). Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch Gen Psychiatry 52:173-181.

Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.

Greden JF, Tandon R (1995). Long-term treatment for lifetime disorders. Arch Gen Psychiatry 52:197-200.

Haase HJ, Janssen PAJ (1958). The Action of Neuroleptic Drugs: A Psychiatric, Neurologic, and Pharmacological Investigation. Year Book Medical Publishers, Chicago Amsterdam.

Harvey PD, Keefe RSE (1997). Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums 2:41-55.

Jain KK (2000). An assessment of iloperidone in the treatment of schizophrenia. Expert Opin Investigat Drugs 9:2935-2943.

Jibson MD, Tandon R (1998). New atypical antipsychotic medications. J Psychiatr Res, 32: 215-228.

Jibson MD, Tandon R (2000). Treatment of schizophrenia. Psychiatr Clin North Am, Annual of Drug Therapy 7:83-113.

Jones B, Taylor CC, Meehan K (2001). The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry (Suppl 2):22-24.

Kales HC, DeQuardo JR, Tandon R (1999). Combined electroconvulsive therapy and clozap-ine in treatment-resistant schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 23: 547-555.

Kane JM (1999). Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-1408.

Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.

Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA (1993). Does clozapine cause tardive dyskinesia? J Clin Psychiatry 54:327-330.

Keefe RSE, Silva SG, Perkins DO, Lieberman JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 25:201-222.

Kraepelin E (1919). Dementia Praecox and Paraphrenia. Translated by Barclay RM and Robertson GM. Edinburgh, E and S Livingstone.

Lehman AF, Steinwachs DM (1998). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24: 1-10.

Maixner SM, Mellow AM, Tandon R (1999). The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 60(Suppl 8):29-43.

Mellman TA, Miller AL, Weissman EM, Crismon ML, Essock SM, Marder SR (2001). Evidence-based pharmacological treatment for people with severe mental illness: A focus on guidelines and algorithms. Psychiatric Services 52:619-625.

Meltzer HY (1995). The concept of atypical antipsychotics. In den Boer JA, Westenberg HGM, van Praag HM (eds). Advances in the Neurobiology of Schizophrenia. Wiley: Chichester, pp. 265-273.

Miller DD, Tandon R (2000). The biology and pathophysiology of negative symptoms. In Keefe R, McEvoy J (eds). Negative Symptoms of Schizophrenia. American Psychiatric Press: Washington DC.

Mojtabai R, Nicholson RA, Carpenter BN (1998). Role of psychosocial treatments in management of schizophrenia: A meta-analytic review of controlled outcome studies. Schizophr Bull 24:569-587.

Otani K, Aoshima T (2000). Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monitoring 22:118-121.

Seeman P, Lee M, Chau-Wong M, et al. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-720.

Slade M, Priebe S (2001). Are randomized controlled trials the only gold that glitters. Br J Psychiatry 179:286-287.

Sumiyoshi T, Matsui M, Yamashita I (2001). The effect of tandospirone, a serotonin (1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861 -868.

Swift RH, Harrigan EP, van Kammen DP (1998). A comparison of intramuscular ziprasidone and intramuscular haloperidol. 9th Congress of the Association of European Psychiatrists, Copenhagen, 20-24 September.

Tandon R (1999). Cholinergic aspects of schizophrenia. Br J Psychiatry 174(suppl 37):7-11.

Tandon R, Greden JF (1989). Cholinergic hyperactivity and negative schizophrenic symptoms: A model of dopaminergic/cholinergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753.

Tandon R, Milner K, Jibson MD (1999a). Antipsychotics from theory to practice: Integrating clinical and basic data. J Clin Psychiatry 60(Suppl 8):20-28.

Tandon R, Taylor SF, DeQuardo JR, Eiser A, Jibson MD, Goldman M (1999b). The cholinergic system in schizophrenia reconsidered. Neuropsychopharmacology 22:S189-202.

Tandon R, Glick I, Goldman M, Jibson MD, Marder SR, Mellman T (2001). Managing Schizophrenia: A Comprehensive Primer. McMahon: New York.

Anxiety and Depression 101

Anxiety and Depression 101

Everything you ever wanted to know about. We have been discussing depression and anxiety and how different information that is out on the market only seems to target one particular cure for these two common conditions that seem to walk hand in hand.

Get My Free Ebook

Post a comment